Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study)

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1513-1520

  Du, Jin ^a   Liang, Li ^b   Fang, Hui ^c   Xu, Fengmei ^d   Li, Wei ^e   Shen, Liya ^f   Wang, Xueying ^g   Xu, Chun ^h   Bian, Fang ⁱ   Mu, Yiming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b People's Hospital of Liaoning Province   (China)

^c Tangshan Gongren Hospital   (China)

^d Hebi Coal Group Co   (China)

^e XUZHOU MEDICAL UNIVERSITY   (China)

^f Wuhan 6th Hospital   (China)

^g Department of Ophthalmology Jinzhou Central Hospital   (China)

^h Chinese People's Armed Police Force General Hospital   (China)

ⁱ People Hospital of Cangzhou   (China)

Author keywords

alpha glucosidase inhibitor; DPP 4 inhibitor; HbA1c; type 2 diabetes

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CHINA; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; DRUG RESISTANCE; ETHNOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; TREATMENT OUTCOME;

ACARBOSE; ADAMANTANE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85021809115     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12942     Document Type: Article

References (33)

1. Chan JC, Zhang Y, Ning G. Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2014;2:969-979.
2. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948-959.
3. Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2:980-991.
4. Gong P, Liang S, Carlton EJ, et al. Urbanisation and health in China. Lancet. 2012;379:843-852.
5. Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8:191-196.
6. Gordon-Larsen P, Wang H, Popkin BM. Overweight dynamics in Chinese children and adults. Obes Rev. 2014;15(suppl 1):37-48.
7. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606-619.
8. Hou X, Liu Y, Lu H, et al. Ten-year changes in the prevalence of overweight, obesity and central obesity among the Chinese adults in urban Shanghai, 1998–2007 – comparison of two cross-sectional surveys. BMC Public Health. 2013;13:1064.
9. Kong AP, Xu G, Brown N, So WY, Ma RC, Chan JC. Diabetes and its comorbidities – where East meets West. Nat Rev Endocrinol. 2013;9:537-547.
10. He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag. 2014;10:505-511.
11. China Diabetes Association. Standards of medical care in type 2 diabetes – 2013. 2013.
12. Sreemantula G, Shankarnarayan S. Non-insulin agents for diabetes. In: Vora J, Evans M, eds. Managing Diabetes. London, England: Springer Healthcare; 2012:61-89.
13. Cai X, Han X, Luo Y, Ji L. Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PLoS ONE. 2013;8:e79421.
14. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435-441.
15. Gu W, Liang L, Wang S, et al. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. J Diabetes. 2016;8(6):809-815.
16. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
18. Sjostrand M, Iqbal N, Lu J, Hirshberg B. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract. 2014;105:185-191.
19. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
20. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011;94:217-224.
21. Wang MM, Lin S, Chen YM, et al. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabetes Res Clin Pract. 2015;108:e67-e70.
22. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28:268-275.
23. Hauber AB, Han S, Yang JC, et al. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence. 2013;7:937-949.
24. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224.
25. Delamater AM. Improving patient adherence. Clin Diabetes. 2006;24:71-77.
26. Price Bureau. Official drug price list. http://www.zjpi.gov.cn/main/html/2014/CT10046/dd72e4240a7e4c1da820a849642f7b37.html. http://www.zjpi.gov.cn/main/html/2014/CT10046/eec3f13a8b2d46258a93966273078df7.html. Accessed December 27, 2014.
27. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23:479-486.
28. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128:159-165.
29. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-2140.
30. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27:79-84.
31. Venn BS, Williams SM, Mann JI. Comparison of postprandial glycaemia in Asians and Caucasians. Diabet Med. 2010;27:1205-1208.
32. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
33. Rosenstock J, Gross JL, Aguilar-Salinas C, et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabet Med. 2013;30:1472-1476.